Understanding the mechanism by which IGF-1 levels fluctuate in patients with OSAHS is critical because studies have shown that lower IGF-1 levels increase the risk of cardiovascular events following ischemic stroke and coronary intervention (50, 51). This evidence concerns the gene IGF1 and ischemic stroke.